NOVN.CH

91.99

-5.47%↓

NOVN.CH

91.99

-5.47%↓

NOVN.CH

91.99

-5.47%↓

NOVN.CH

91.99

-5.47%↓

NOVN.CH

91.99

-5.47%↓

Search

Lonza Group AG

Închisă

SectorSănătate

511 -4.63

Rezumat

Modificarea prețului

24h

Curent

Minim

506.2

Maxim

511.6

Indicatori cheie

By Trading Economics

Venit

329M

Vânzări

3.1B

P/E

Medie Sector

60.853

63.778

EPS

4.31

Randament dividend

0.71

Marjă de profit

10.762

Angajați

18,686

EBITDA

824M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+24.87% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.71%

2.39%

Statistici piață

By TradingEconomics

Capitalizare de piață

-3B

39B

Deschiderea anterioară

515.63

Închiderea anterioară

511

Sentimentul știrilor

By Acuity

100%

0%

375 / 386 Clasament în Healthcare

Lonza Group AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 feb. 2025, 12:22 UTC

Achiziții, Fuziuni, Preluări

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

12 dec. 2024, 09:26 UTC

Achiziții, Fuziuni, Preluări

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

12 dec. 2024, 07:45 UTC

Achiziții, Fuziuni, Preluări

Lonza Streamlines Business With Capsules Unit Exit -- Update

12 dec. 2024, 06:52 UTC

Achiziții, Fuziuni, Preluări

Lonza Streamlines Organizational Structure

24 oct. 2024, 05:40 UTC

Câștiguri

Lonza Expects Accelerating Sales Growth in Final Quarter

29 ian. 2025, 08:11 UTC

Market Talk
Câștiguri

Lonza's Outlook Looks Positive -- Market Talk

29 ian. 2025, 07:22 UTC

Market Talk
Câștiguri

Lonza Had a Mixed Year Across Divisions -- Market Talk

29 ian. 2025, 07:11 UTC

Market Talk
Câștiguri

Lonza's Results Don't Contain Any Surprises -- Market Talk

29 ian. 2025, 06:26 UTC

Top știri
Câștiguri

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

16 ian. 2025, 10:32 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Lonza's Midterm Outlook Is Positive -- Market Talk

16 dec. 2024, 22:03 UTC

Top știri

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 dec. 2024, 08:07 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

12 dec. 2024, 08:51 UTC

Market Talk
Câștiguri
Achiziții, Fuziuni, Preluări

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

12 dec. 2024, 08:02 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

12 dec. 2024, 05:59 UTC

Achiziții, Fuziuni, Preluări

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

12 dec. 2024, 05:59 UTC

Achiziții, Fuziuni, Preluări

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

12 dec. 2024, 05:58 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

12 dec. 2024, 05:58 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

12 dec. 2024, 05:58 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

12 dec. 2024, 05:57 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

12 dec. 2024, 05:55 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

12 dec. 2024, 05:54 UTC

Achiziții, Fuziuni, Preluări

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

12 dec. 2024, 05:54 UTC

Achiziții, Fuziuni, Preluări

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

12 dec. 2024, 05:53 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees 2024 Core Ebitda Margin of 27-29%

12 dec. 2024, 05:53 UTC

Achiziții, Fuziuni, Preluări

Lonza Sees Flat 2024 CER Sales Growth

12 dec. 2024, 05:52 UTC

Achiziții, Fuziuni, Preluări

Lonza Backs 2024 View

12 dec. 2024, 05:52 UTC

Achiziții, Fuziuni, Preluări

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

12 dec. 2024, 05:52 UTC

Achiziții, Fuziuni, Preluări

Lonza to Exit Capsules, Health Ingredients Business at Appropriate Time

12 dec. 2024, 05:51 UTC

Achiziții, Fuziuni, Preluări

Lonza Outlines Strategy, New Organizational Structure and Guidance

24 oct. 2024, 06:37 UTC

Market Talk
Câștiguri

Lonza 3Q Update Didn't Surprise -- Market Talk

Comparație

Modificare preț

Lonza Group AG Așteptări

Obiectiv de preț

By TipRanks

24.87% sus

Prognoză pe 12 luni

Medie 670.54 CHF  24.87%

Maxim 744 CHF

Minim 625 CHF

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLonza Group AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

9

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

375 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.